ResearcherSheba Medical CenterActive in the last 2 years

Ronnie Shapira‐Frommer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6170-080X; OpenAlex author ID A5058238015. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2026: 1 paper

Papers 1

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 St… Last author DOI 10.1158/2767-9764.crc-26-0018 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tae Won Kim · 1 shared paper, 2026 · strength 0.23
- Paper Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cance… DOI 10.1158/2767-9764.crc-26-0018 ↗
Mariano Ponz‐Sarvisé · 1 shared paper, 2026 · strength 0.23
- Paper Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cance… DOI 10.1158/2767-9764.crc-26-0018 ↗
Armando Santoro · 1 shared paper, 2026 · strength 0.23
- Paper Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cance… DOI 10.1158/2767-9764.crc-26-0018 ↗
Giampaolo Tortora · 1 shared paper, 2026 · strength 0.23
- Paper Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cance… DOI 10.1158/2767-9764.crc-26-0018 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.